HealthyPhase 1NCT06816719
To Evaluate the Safety and PK Characteristics in Healthy Volunteers-JW24107
A Phase 1 study testing Treatment A: JW0106 1 tablet + C2101 1 tablet and Treatment B: JW0107 1 tablet in people with Healthy, run by JW Pharmaceutical at 1 site in South Korea.
Trial summary
The objective is to evaluate the safety and pharmacokinetic characteristics after co-administration of JW0106 and C2101 and administration of JW0107 in healthy volunteers under fasting conditions. Read more about this study
- Who is it for?
- Ages 19 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Treatment A: JW0106 1 tablet + C2101 1 tablet and Treatment B: JW0107 1 tablet
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 47 participants
- Where
- 1 siteSouth Korea
- Study dates
- 2 Sep 2024to 12 Nov 2024
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy volunteers
Who cannot join
- Subjects does not meet the inclusion Criteria
Trial locations and contacts
1 site in 1 country.
South Korea1 site
Clinical Trial Center, Jeonbuk National University Hospital
Jeonju, Korea
About this study
Official title: A Randomized, Open-label, Single Dose, 2x4 Crossover Study to Evaluate the Safety and Pharmacokinetic Characteristics After Co-administration of JW0106 and C2101 and Administration of JW0107 in Healthy Volunteers Under Fasting Conditions
The objective is to evaluate the safety and pharmacokinetic characteristics after co-administration of JW0106 and C2101 and administration of JW0107 in healthy volunteers under fasting conditions.
Read the detailed description
Pharmacokinetic characteristics: Describes the blood concentration statistically by pharmacokinetic blood collection time and treatment group.
Safety: All adverse events are summarized in terms of the number of subjects, expression rate, and number of expressions of adverse reactions by treatment group.
- Conditions
- Healthy
- Being tested
- Treatment A: JW0106 1 tablet + C2101 1 tablet, Treatment B: JW0107 1 tablet
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Treatment A: JW0106 1 tablet + C2101 1 tabletDrug
- Co-administration of 1 tablet of JW0106 and 1 tablet of C2101
- Administration orally with 150 mL of water under fasting conditions
Treatment B: JW0107 1 tabletDrug
Also called Administration alone of 1 tablet of JW0107
- Administration alone of 1 tablet of JW0107
- Administration orally with 150 mL of water under fasting conditions
| Study group | Role | What they receive |
|---|---|---|
| Sequence 1 | Other | (Period 1/3: Treatment A) (Period 2/4: Treatment B)
Treatment A: JW0106 1 tablet + C2101 1 tablet Treatment B: JW0107 1 tablet Receives: Drug: Treatment A: JW0106 1 tablet + C2101 1 tablet; Drug: Treatment B: JW0107 1 tablet |
| Sequence 2 | Other | (Period 1/3: Treatment B) (Period 2/4: Treatment A)
Treatment A: JW0106 1 tablet + C2101 1 tablet Treatment B: JW0107 1 tablet Receives: Drug: Treatment A: JW0106 1 tablet + C2101 1 tablet; Drug: Treatment B: JW0107 1 tablet |
What is being measured
The primary outcome is the main question the study is designed to answer.
AUCt
Describes the blood concentration statistically by pharmacokinetic blood collection time and treatment group.
Measured: Day 1(0 hour~12 hour), Day 2(24 hour), Day 3(48 hour), Day 4(72 hour)
Cmax
Describes the blood concentration statistically by pharmacokinetic blood
Measured: Day 1(0 hour~12 hour), Day 2(24 hour), Day 3(48 hour), Day 4(72 hour)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Feb 2025
- Study start2 Sep 2024
- Primary completion2 Nov 2024
- Study completion12 Nov 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 47 participants (actual)
Sponsor and investigators
- Lead sponsor
- JW Pharmaceutical
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06816719
- Sponsor's protocol ID
- JW24107
- Status last verified
- Feb 2025
- First submitted
- 1 Jan 2025
- Last updated
- 10 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Open-label, Single Dose, 2x4 Crossover Study to Evaluate the Safety and Pharmacokinetic Characteristics After Co-administration of JW0106 and C2101 and Administration of JW0107 in Healthy Volunteers Under Fasting Conditions
- ClinicalTrials.gov ID
- NCT06816719
- Acronym / sponsor ID
- JW24107
- Conditions
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 47 participants (actual)
- Lead sponsor
- JW PharmaceuticalIndustry (pharma, biotech, devices)
- Study start
- 2 Sep 2024 (actual)
- Primary completion
- 2 Nov 2024 (actual)
- Study completion
- 12 Nov 2024 (actual)
- First posted
- 10 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective is to evaluate the safety and pharmacokinetic characteristics after co-administration of JW0106 and C2101 and administration of JW0107 in healthy volunteers under fasting conditions.
Detailed description
Pharmacokinetic characteristics: Describes the blood concentration statistically by pharmacokinetic blood collection time and treatment group.
Safety: All adverse events are summarized in terms of the number of subjects, expression rate, and number of expressions of adverse reactions by treatment group.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Sequence 1 | Other | Drug: Treatment A: JW0106 1 tablet + C2101 1 tablet, Drug: Treatment B: JW0107 1 tablet(Period 1/3: Treatment A) (Period 2/4: Treatment B) Treatment A: JW0106 1 tablet + C2101 1 tablet Treatment B: JW0107 1 tablet |
| Sequence 2 | Other | Drug: Treatment A: JW0106 1 tablet + C2101 1 tablet, Drug: Treatment B: JW0107 1 tablet(Period 1/3: Treatment B) (Period 2/4: Treatment A) Treatment A: JW0106 1 tablet + C2101 1 tablet Treatment B: JW0107 1 tablet |
Who may qualify
- Ages
- 19 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Healthy volunteers
Key exclusion criteria (1 listed)
- Subjects does not meet the inclusion Criteria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Treatment A: JW0106 1 tablet + C2101 1 tablet* Co-administration of 1 tablet of JW0106 and 1 tablet of C2101 * Administration orally with 150 mL of water under fasting conditions | Drug | Sequence 1, Sequence 2 |
| Treatment B: JW0107 1 tabletAlso: Administration alone of 1 tablet of JW0107* Administration alone of 1 tablet of JW0107 * Administration orally with 150 mL of water under fasting conditions | Drug | Sequence 1, Sequence 2 |
Primary outcome
AUCt
Time frame: Day 1(0 hour~12 hour), Day 2(24 hour), Day 3(48 hour), Day 4(72 hour)
Describes the blood concentration statistically by pharmacokinetic blood collection time and treatment group.
Cmax
Time frame: Day 1(0 hour~12 hour), Day 2(24 hour), Day 3(48 hour), Day 4(72 hour)
Describes the blood concentration statistically by pharmacokinetic blood
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Feb 2025.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Treatment A: JW0106 1 tablet + C2101 1 tablet and Treatment B: JW0107 1 tablet in people with Healthy, run by JW Pharmaceutical at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
AUCt (time frame: Day 1(0 hour~12 hour), Day 2(24 hour), Day 3(48 hour), Day 4(72 hour)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2025.